Jason Bednar
Stock Analyst at Piper Sandler
(2.11)
# 2,844
Out of 5,182 analysts
208
Total ratings
37.18%
Success rate
-4.33%
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALGN Align Technology | Maintains: Overweight | $220 → $235 | $177.28 | +32.56% | 34 | Apr 21, 2026 | |
| SOLV Solventum | Maintains: Overweight | $98 → $92 | $67.51 | +36.28% | 9 | Apr 17, 2026 | |
| MMSI Merit Medical Systems | Maintains: Overweight | $106 → $96 | $66.74 | +43.84% | 16 | Apr 17, 2026 | |
| ICUI ICU Medical | Maintains: Overweight | $178 → $163 | $121.11 | +34.59% | 5 | Apr 17, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Overweight | $96 → $88 | $68.50 | +28.47% | 3 | Apr 17, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $170 → $159 | $149.52 | +6.34% | 14 | Apr 17, 2026 | |
| DRTS Alpha Tau Medical | Downgrades: Neutral | $5 | $7.30 | -31.51% | 6 | Mar 4, 2026 | |
| NVST Envista Holdings | Reiterates: Neutral | $21 → $25 | $26.49 | -5.62% | 15 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Overweight | $50 | $44.24 | +13.02% | 1 | Jan 12, 2026 | |
| SHC Sotera Health Company | Upgrades: Overweight | $17 → $24 | $15.54 | +54.44% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $83 → $94 | $63.09 | +48.99% | 15 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $4 | $4.08 | -1.96% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $210 | $178.51 | +17.64% | 16 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $9 → $2.5 | $1.23 | +103.25% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $12.12 | +180.53% | 11 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $11.78 | +35.82% | 8 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $77 | $76.12 | +1.16% | 7 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.28 | +37.20% | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $265 | $219.75 | +20.59% | 9 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $2.04 | +194.12% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $20 | $0.51 | +3,828.50% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $466.64 | -20.28% | 4 | Jan 3, 2024 |
Align Technology
Apr 21, 2026
Maintains: Overweight
Price Target: $220 → $235
Current: $177.28
Upside: +32.56%
Solventum
Apr 17, 2026
Maintains: Overweight
Price Target: $98 → $92
Current: $67.51
Upside: +36.28%
Merit Medical Systems
Apr 17, 2026
Maintains: Overweight
Price Target: $106 → $96
Current: $66.74
Upside: +43.84%
ICU Medical
Apr 17, 2026
Maintains: Overweight
Price Target: $178 → $163
Current: $121.11
Upside: +34.59%
GE HealthCare Technologies
Apr 17, 2026
Maintains: Overweight
Price Target: $96 → $88
Current: $68.50
Upside: +28.47%
Becton, Dickinson and Company
Apr 17, 2026
Maintains: Neutral
Price Target: $170 → $159
Current: $149.52
Upside: +6.34%
Alpha Tau Medical
Mar 4, 2026
Downgrades: Neutral
Price Target: $5
Current: $7.30
Upside: -31.51%
Envista Holdings
Feb 6, 2026
Reiterates: Neutral
Price Target: $21 → $25
Current: $26.49
Upside: -5.62%
Medline
Jan 12, 2026
Initiates: Overweight
Price Target: $50
Current: $44.24
Upside: +13.02%
Sotera Health Company
Jan 9, 2026
Upgrades: Overweight
Price Target: $17 → $24
Current: $15.54
Upside: +54.44%
Dec 5, 2025
Reiterates: Overweight
Price Target: $83 → $94
Current: $63.09
Upside: +48.99%
Aug 7, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $4.08
Upside: -1.96%
Aug 6, 2025
Maintains: Overweight
Price Target: $200 → $210
Current: $178.51
Upside: +17.64%
Jul 31, 2025
Downgrades: Neutral
Price Target: $9 → $2.5
Current: $1.23
Upside: +103.25%
Jun 27, 2025
Reiterates: Overweight
Price Target: $34
Current: $12.12
Upside: +180.53%
Apr 30, 2025
Maintains: Neutral
Price Target: $20 → $16
Current: $11.78
Upside: +35.82%
Apr 30, 2025
Maintains: Overweight
Price Target: $83 → $77
Current: $76.12
Upside: +1.16%
Mar 28, 2025
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.28
Upside: +37.20%
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $219.75
Upside: +20.59%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $2.04
Upside: +194.12%
Aug 7, 2024
Maintains: Overweight
Price Target: $70 → $20
Current: $0.51
Upside: +3,828.50%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $466.64
Upside: -20.28%